Endonovo Therapeutics, Inc. Stock Other OTC
Equities
ENDV
US29272H3003
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 0.07 | Sales 2022 | 0.14 | Capitalization | 3.5M |
---|---|---|---|---|---|
Net income 2021 | -3M | Net income 2022 | -18M | EV / Sales 2021 | 112,421,804 x |
Net Debt 2021 | 7.1M | Net Debt 2022 | 7.15M | EV / Sales 2022 | 78,689,579 x |
P/E ratio 2021 |
-0.3
x | P/E ratio 2022 |
-0.14
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.47% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 12-02-29 |
Don Calabria
COO | Chief Operating Officer | 53 | - |
Steven Barnes
IRC | Investor Relations Contact | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 12-02-29 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |